Skip to main content
. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z

Fig. 1.

Fig. 1

Table of the Cancer Immunotherapy Guidelines for Hematologic Malignancy participants. Asterisks (*) indicate panel chair and steering committee member